Dr. Schulman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 Route 112 Bldg 4 Ste 101
Port Jefferson Station, NY 11776Phone+1 631-751-3000Fax+1 631-509-6559
Education & Training
- Icahn School of Medicine at Mount Sinai (Cabrini)Residency, Internal Medicine, 1974 - 1977
- SUNY Upstate Medical UniversityClass of 1974
Certifications & Licensure
- CT State Medical License 2024 - 2025
- NY State Medical License 1975 - 2025
- PA State Medical License 2022 - 2024
- FL State Medical License 2021 - 2023
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 25 citationsHigh dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.Richard Stone, Barry K. Moser, Ben L. Sanford, Philip Schulman, Jonathan E. Kolitz
Leukemia Research. 2011-03-01 - 181 citationsPhase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patient...Eric J. Feldman, Joseph Brandwein, Richard Stone, Matt Kalaycio, Joseph O. Moore
Journal of Clinical Oncology. 2005-06-20 - 66 citationsTreatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.Eric J. Feldman, Matt Kalaycio, G. Weiner, Stanley R. Frankel, P. Schulman
Leukemia. 2003-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: